eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention.
. picks two weeks ago, the second time in four years he's nailed the race's top-three finishers.) but getting to this point was a long road.
.
.
.
fremanezumab has completed phase iii trials and is under review by the fda to prevent migraine and
.